Want to see TLRY full AI Analyst Report?
TLRY Stock Chart & Stats
$4.64
$0.15(3.87%)
At close: 4:00 PM EDT
$4.64
$0.15(3.87%)
Day’s Range― - ―
52-Week Range$3.67 - $23.20
Previous Close$4.04
Volume3.69M
Average Volume (3M)4.21M
Market Cap
$573.42M
Enterprise Value$780.77
Total Cash (Recent Filing)$231.27M
Total Debt (Recent Filing)$398.40M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Oct 01, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.33
Shares Outstanding136,203,580
10 Day Avg. Volume3,061,411
30 Day Avg. Volume4,212,211
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.38
Price to Sales (P/S)0.67
P/FCF Ratio-6.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$6.13Price Target Upside32.00% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.5
Revenue Forecast (FY)$1.12B
Bulls Say, Bears Say
Bulls Say
International Cannabis Growth And CapacityStrong international cannabis growth, rising medical flower volumes, and expanded Portuguese production provide a scalable platform beyond the Canadian market. Higher utilization and supply capacity can support revenue growth, improve operating leverage, and strengthen Tilray’s position as legal medical markets develop.
Improved Liquidity And Lower LeverageNear-zero net debt and substantial liquidity give Tilray greater flexibility to fund operations, manage volatility, and pursue targeted growth initiatives. Debt reduction also lowers financial obligations, making the balance sheet more supportive while management works toward profitability and positive cash generation.
Broadening Consumer And Distribution PlatformGrowth across distribution and beverages broadens Tilray beyond cannabis and adds multiple routes to consumers. CC Pharma’s reach, the BrewDog platform, and the Carlsberg partnership can improve scale, market access, and brand distribution, supporting a more diversified long-term revenue base.
Bears Say
Persistent Losses And Negative Free Cash FlowContinued net losses and negative free cash flow show that Tilray has not yet converted its operations into self-funded growth. Ongoing cash needs can constrain investment, increase reliance on financing or liquidity reserves, and make the company more vulnerable if margin improvement takes longer than expected.
International Cannabis Price CompressionPrice compression directly limits the earnings benefit of international volume growth by reducing revenue realized per unit and compressing gross profit. If competitive or regulatory market dynamics persist, Tilray may need further cost reductions and operational efficiencies just to protect margins.
BrewDog Working-capital Cash StrainThe BrewDog integration is consuming meaningful working capital and delaying conversion of reported revenue into cash. This can weaken near-term liquidity efficiency, increase execution demands across the enlarged beverage platform, and postpone the point at which consolidated operations generate sustainable free cash flow.
Tilray News
TLRY FAQ
What was Tilray’s price range in the past 12 months?
Tilray lowest stock price was $3.67 and its highest was $23.20 in the past 12 months.
What is Tilray’s market cap?
Tilray’s market cap is $573.42M.
When is Tilray’s upcoming earnings report date?
Tilray’s upcoming earnings report date is Oct 01, 2026 which is in 20 days.
How were Tilray’s earnings last quarter?
Tilray released its earnings results on Jul 28, 2026. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.012 by -$0.418.
Is Tilray overvalued?
According to Wall Street analysts Tilray’s price is currently Undervalued.
Does Tilray pay dividends?
Tilray does not currently pay dividends.
What is Tilray’s EPS estimate?
Tilray’s EPS estimate is -0.17.
How many shares outstanding does Tilray have?
Tilray has 136,203,580 shares outstanding.
What happened to Tilray’s price movement after its last earnings report?
Tilray reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.012. Following the earnings report the stock price went down -0.993%.
Which hedge fund is a major shareholder of Tilray?
Currently, no hedge funds are holding shares in TLRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tilray Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$6.13 (32.00% Upside)
$6.13 (32.00% Upside)
Blogger Sentiment
Bullish
TLRY Sentiment 67%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 359.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $69.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
11.31%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Tilray
Tilray Brands, Inc. is a diversified global consumer packaged goods company primarily involved in the cultivation, processing, marketing, and sale of cannabis products. Its operations span a significant international footprint, encompassing Canada, the United States, Europe, Australia, New Zealand, and Latin America. The company organizes its business across four distinct divisions: Cannabis, Distribution, Beverage Alcohol, and Wellness. Within its cannabis division, Tilray provides a comprehensive range of medical and adult-use items, including regulated products like GMP-certified cannabis flowers, oils, vaporizers, edibles, and topical applications. Beyond cannabis, Tilray's portfolio extends to the procurement and resale of pharmaceutical and wellness goods. Furthermore, it manufactures, promotes, and distributes a variety of alcoholic beverages, alongside hemp-derived food and other wellness items. The company markets its diverse offerings under numerous recognized brands, such as Tilray, Aphria, SweetWater, and Breckenridge Distillery. Its products reach a wide array of customers, including retail outlets, wholesale partners, medical patients, healthcare practitioners, hospitals, pharmacies, scientific researchers, governmental bodies, and directly to end consumers. Formerly operating as Tilray, Inc., the corporation is headquartered in Leamington, Canada.
TLRY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted meaningful operational progress: record revenue and adjusted EBITDA, stronger liquidity (≈$235M cash) and near-zero net debt, substantial international cannabis and distribution growth, and strategic beverage expansion through the BrewDog acquisition and the Carlsberg partnership. At the same time, challenges remain including a FY2026 net loss of $105.2M, negative adjusted free cash flow (negative $86M), international price compression (~$21M), legacy U.S. beverage headwinds, and significant working capital tied up in the BrewDog transaction. Overall the company presented a pathway to higher margins and cash generation but still faces execution and market-mix headwinds in the near term.View all TLRY earnings summariesTLRY Stock 12 Month Forecast
Average Price Target
$6.13
▲(32.00% Upside)
Technical Analysis
Ownership Overview
2.19% Insiders
0.36% Mutual Funds
0.78% Other Institutional Investors
93.53% Public Companies and
Individual Investors